Abstract
The obesity pandemic will likely have a significant impact on the global incidence of cardiovascular disease. Although the mechanisms linking obesity and cardiovascular disease are unclear, recent studies have implicated the adipocyte as a potentially important mediator of vascular complications. The adipocyte is no longer considered a passive storage depot for triglycerides and fatty acids, but rather an active metabolic organ capable of producing several factors, commonly referred to as adipokines, that may have effects on many physiological and pathophysiological processes. With increasing fat mass, several adipose-related factors are upregulated that may affect local and distant inflammatory processes, including atherothrombosis. Other factors, such as adiponectin, are downregulated with increasing fat mass. Although most adipokines are thought to promote vascular disease, several studies over the past few years indicate adiponectin is actually protective against both diabetes and vascular disease. There are now available pharmacologic agents capable of altering the adipocyte transcription profile. This review will focus on the potential impact of adipocyte-derived factors towards vascular disease and emerging therapeutic strategies that may alter these effects.
Keywords: Thrombosis, adipose, diabetes, hemostasis, atherosclerosis
Current Vascular Pharmacology
Title: Strategies to Reduce Vascular Risk Associated with Obesity
Volume: 5 Issue: 4
Author(s): Peter F. Bodary, Heidi B. Iglay and Daniel T. Eitzman
Affiliation:
Keywords: Thrombosis, adipose, diabetes, hemostasis, atherosclerosis
Abstract: The obesity pandemic will likely have a significant impact on the global incidence of cardiovascular disease. Although the mechanisms linking obesity and cardiovascular disease are unclear, recent studies have implicated the adipocyte as a potentially important mediator of vascular complications. The adipocyte is no longer considered a passive storage depot for triglycerides and fatty acids, but rather an active metabolic organ capable of producing several factors, commonly referred to as adipokines, that may have effects on many physiological and pathophysiological processes. With increasing fat mass, several adipose-related factors are upregulated that may affect local and distant inflammatory processes, including atherothrombosis. Other factors, such as adiponectin, are downregulated with increasing fat mass. Although most adipokines are thought to promote vascular disease, several studies over the past few years indicate adiponectin is actually protective against both diabetes and vascular disease. There are now available pharmacologic agents capable of altering the adipocyte transcription profile. This review will focus on the potential impact of adipocyte-derived factors towards vascular disease and emerging therapeutic strategies that may alter these effects.
Export Options
About this article
Cite this article as:
Bodary F. Peter, Iglay B. Heidi and Eitzman T. Daniel, Strategies to Reduce Vascular Risk Associated with Obesity, Current Vascular Pharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157016107782023415
DOI https://dx.doi.org/10.2174/157016107782023415 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Food Addiction and Neuroimaging
Current Pharmaceutical Design Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) Impact of Macrophages in Atherosclerosis
Current Medicinal Chemistry Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology CGRP, a Vasodilator Neuropeptide that Stimulates Neuromuscular Transmission and EC Coupling
Current Vascular Pharmacology Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Effect of Handgrip Exercise on QTc Interval During Different Phases of Menstrual Cycle
Vascular Disease Prevention (Discontinued) MRI Contrast Agents: Current Status and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry The Effects of Zataria Multiflora on Blood Glucose, Lipid Profile and Oxidative Stress Parameters in Adult Mice During Exposure to Bisphenol A
Cardiovascular & Hematological Disorders-Drug Targets Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Current Medicinal Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy